OncoMatch/Clinical Trials/NCT04465500
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
Is NCT04465500 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Androgen Deprivation Therapy for prostate cancer.
Treatment: Androgen Deprivation Therapy — This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, and overall survival for patients receiving this treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radical surgery (prostatectomy)
Patient has had previous radical surgery (prostatectomy) or cryosurgery for prostate cancer.
Cannot have received: cryosurgery
Patient has had previous radical surgery (prostatectomy) or cryosurgery for prostate cancer.
Cannot have received: pelvic irradiation
Patient has had previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy.
Cannot have received: prostate brachytherapy
Patient has had previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy.
Cannot have received: bilateral orchiectomy
Patient has had previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy.
Cannot have received: radiotherapy (including brachytherapy) to the region of this study cancer that would result in overlap of radiation therapy fields
Patient has had prior radiotherapy, including brachytherapy, to the region of this study cancer that would result in overlap of radiation therapy fields.
Cannot have received: cytotoxic chemotherapy for prostate cancer
Exception: prior chemotherapy for different cancer is allowed
Patient has had previous or concurrent cytotoxic chemotherapy for prostate cancer (prior chemotherapy for different cancer is allowed).
Lab requirements
Liver function
Hepatic insufficiency resulting in clinical jaundice and/or coagulation effects or severe liver dysfunction [excluded].
Cardiac function
Unstable angina and/or congestive heart failure requiring hospitalization up to 6 months before registration; transmural myocardial infarction up to 6 months before registration [excluded].
Unstable angina and/or congestive heart failure requiring hospitalization up to 6 months (180 days) before registration; Transmural myocardial infarction up to 6 months (180 days) before registration; Hepatic insufficiency resulting in clinical jaundice and/or coagulation effects or severe liver dysfunction.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Virginia · Charlottesville, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify